Colon Tumor Antigen Specific Neutra™ Antibody Products

Are you facing challenges in prolonged drug development cycles or achieving consistent antibody specificity in colorectal cancer research? Creative Biolabs' colon tumor antigen specific Neutra™ antibody products leverage advanced protein engineering and high-throughput validation to deliver high-affinity reagents that streamline target validation, enhance therapeutic efficacy, and accelerate translational outcomes.

Introduction to Colon Tumor Antigen

Colon tumor antigen is a clinically significant biomarker and therapeutic target overexpressed in colorectal cancer (CRC) cells. This glycoprotein plays a critical role in tumor progression, metastasis, and immune evasion. Its expression correlates with advanced disease stages and resistance to conventional therapies, making it a focal point for diagnostic and therapeutic innovation.

Fig.1 The different CRC antigens.¹

• Structural Insights

The antigen features a transmembrane domain and multiple extracellular epitopes, enabling it to interact with host cell receptors and extracellular matrix components. Its tertiary structure facilitates homodimerization, which is essential for activating downstream signaling cascades. Recent structural studies highlight conformational flexibility in its ligand-binding regions, a property exploitable for designing neutralizing antibodies.

• Related Signaling Pathways

Colon tumor antigen modulates pathways central to CRC pathogenesis:

1. EGFR/MAPK Signaling: Promotes cell proliferation and survival.

2. Angiogenesis (VEGF/VEGFR): Enhances tumor vascularization.

3. Immune Checkpoint Regulation: Suppresses T-cell activity via PD-L1 upregulation.

Emerging research reveals cross-talk with mitochondrial enzymes, such as those targeted by the microbial metabolite 2-MiCit, which synergizes with chemotherapy to induce DNA damage and apoptosis in CRC cells.

• Associated Diseases

Colorectal cancer, the third most common malignancy globally, is characterized by high recurrence rates and heterogeneous treatment responses. The antigen's role in mediating chemoresistance—particularly to 5-fluorouracil (5-FU)—underscores its clinical relevance. Innovations like microbial-derived metabolites (e.g., 2-MiCit) demonstrate how targeting this antigen can amplify chemotherapy efficacy, offering new avenues for combination therapies.

Applications of Colon Tumor Antigen Neutralizing Antibodies

• Therapeutic Development

These antibodies form the backbone of CRC-targeted therapies, such as antibody-drug conjugates (ADCs) and bispecific platforms. By blocking pro-tumorigenic signaling, they reduce metastatic potential and enhance the activity of chemotherapeutics like 5-FU.

• Diagnostic Biomarker Profiling

Enable early detection and patient stratification through quantitative antigen measurement in serum or tissue biopsies. High specificity ensures accurate monitoring of treatment responses and minimal false positives.

• Immunotherapy Enhancement

Synergize with immune checkpoint inhibitors (e.g., anti-PD-1) by counteracting antigen-mediated immunosuppression. Preclinical data show improved T-cell infiltration and tumor regression in combination regimens.

• Preclinical Research Tools

Facilitate mechanistic studies into CRC pathogenesis, including CRISPR-edited cell lines and patient-derived xenograft (PDX) models. Researchers can map antigen dynamics during tumor evolution or therapeutic intervention.

Our Anti-Colon Tumor Antigen Antibodies

Creative Biolabs' anti-Colon Tumor Antigen Neutralizing Antibodies are engineered for unparalleled specificity and functional blockade. Key features include:

- High Affinity: Detect picomolar antigen concentrations in complex biological samples.

- Cross-Application Compatibility: Validated for ELISA, immunohistochemistry (IHC), and flow cytometry.

- Functional Neutralization: Inhibit antigen-receptor interactions, disrupting oncogenic signaling and restoring chemosensitivity in preclinical models.

Creative Biolabs' colon tumor antigen specific Neutra™ antibody products empower researchers and clinicians to overcome CRC's complexity with precision tools. From target validation to clinical translation, our antibodies are rigorously optimized for reliability and impact.

Contact our team today to discuss your project and explore how our solutions can accelerate your breakthroughs.

REFERENCE

1. Aparicio, Cristina, et al. "Cell therapy for colorectal cancer: the promise of chimeric antigen receptor (CAR)-T cells." International Journal of Molecular Sciences 22.21 (2021): 11781. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms222111781